Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11398245 | 0.89 | DAO (0.68) | DAORAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2913260 | 0.87 | DAO (0.66) | DAORAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL11407858 | 0.86 | DAO (0.64) | DAOKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL352306 | 0.84 | DAO (1.00) | DAORAB9ANPC1SMN1; SMN2TP53 | |
| Methane SCHEMBL28127314 | 0.82 | DAO (0.96) | DAORAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4171556 | 0.78 | DAO (0.68) | DAORAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL30295668 | 0.77 | DAO (0.67) | DAORAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL13614249 | 0.76 | DAO (0.66) | DAORAB9ATP53ALDH1A1GAA | |
| SCHEMBL3635029 | 0.76 | DAO (0.66) | DAORAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL13894452 | 0.76 | DAO (0.66) | DAORAB9ATP53GAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | claimed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20100331338-A1 | Glucokinase Activators | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| CN-1019490-B | METHOD FOR PRODUCING 3-(1H-TETRAZOL-5-YL) THIENO 2,3-DLPYRIMIDIN-4(3H)-ONES | MERRELL DOW PHARMA (US) | 1992-12-16 | — | — | CN | disclosed |
| CN-87100912-A | 3-(1-H-tetrazolium-5-yl) thieno-[2,3-d] pyrimidines-4 (3H)-ketone | — | 1987-12-23 | — | — | CN | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331338-A1 | Glucokinase Activators | GCKR, HK1, GCK | DAO 3110/4885RAB9A 2651/4885NPC1 1277/4885 |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | DAO 255/4885RAB9A 1383/4885NPC1 3841/4885 |
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | DAO 3340/4885RAB9A 2682/4885NPC1 53/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | DAO 3327/4885RAB9A 1216/4885NPC1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.